ArticlePloS one2026
Burden of respiratory syncytial virus (RSV) hospitalizations among adults aged 60 years or more in Brazil: A retrospective surveillance database analysis (2013-2024).
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobally, respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness in adults aged ≥60 years. Risk increases with advancing age and comorbidities, particularly cardiopulmonary disease and diabetes. RSV disease burden in adults is often underestimated due to non-specific presentation and limited testing. In Brazil, RSV is a recognized driver of hospitalizations and deaths in older adults, yet comprehensive epidemiological data remain scarce. Here, we describe RSV-associated severe acute respiratory infection (SARI) hospitalizations among adults aged ≥60 years in Brazil between 2013 and 2024.
methodsWe retrospectively analyzed RSV-associated SARI hospitalizations reported to the national Influenza Epidemiological Surveillance Information System -Gripe. Outcomes included hospitalization frequency, in-hospital mortality, case fatality rates (CFRs), seasonality, healthcare resource utilization, and comorbidities.
resultsBetween 2013 and 2024, 4,636 RSV-related hospitalizations occurred in adults aged ≥60 years, increasing sharply after the COVID-19 pandemic (2020-2024). Hospitalization rates increased from <1 per 100,000 in 2013 to >15 per 100,000 in 2024. Women accounted for most cases (59%), and hospitalizations were concentrated in the South and Southeast regions partly due to test availability. In-hospital mortality increased over time, with mean rates nearly fivefold higher post-pandemic than pre-pandemic. CFRs remained consistently high (21-31%), particularly in adults aged ≥80 years. The mean length of hospital stay was 12.9 days. Almost one-third of cases required intensive care unit admission, of whom more than two-thirds needed ventilatory support. Comorbidities were present in 71% of cases, most commonly cardiovascular (65%) and diabetes (33%)were strongly associated with increased mortality and healthcare resource utilization.
conclusionsRSV poses a substantial and increasing burden among Brazilian adults aged ≥60 years, with a high CFR, prolonged hospitalizations, and intensive healthcare resource utilization. These findings highlight the need to strengthen RSV surveillance and discuss vaccination strategies for adults aged older in Brazil.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.